These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30742559)

  • 1. Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.
    McNeer JL; Devidas M; Dai Y; Carroll AJ; Heerema NA; Gastier-Foster JM; Kahwash SB; Borowitz MJ; Wood BL; Larsen E; Maloney KW; Mattano L; Winick NJ; Schultz KR; Hunger SP; Carroll WL; Loh ML; Raetz EA
    J Clin Oncol; 2019 Apr; 37(10):780-789. PubMed ID: 30742559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia.
    Bai L; Cheng YF; Lu AD; Suo P; Wang Y; Zuo YX; Yan CH; Wu J; Jia YP; Sun YQ; Chen YH; Chen H; Liu KY; Han W; Xu LP; Wang JB; Tang XF; Chen HR; Zhang LP; Huang XJ
    Leuk Res; 2020 Apr; 91():106333. PubMed ID: 32109757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
    PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
    Schultz KR; Pullen DJ; Sather HN; Shuster JJ; Devidas M; Borowitz MJ; Carroll AJ; Heerema NA; Rubnitz JE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Gaynon PS; Camitta BM
    Blood; 2007 Feb; 109(3):926-35. PubMed ID: 17003380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
    Eckert C; Groeneveld-Krentz S; Kirschner-Schwabe R; Hagedorn N; Chen-Santel C; Bader P; Borkhardt A; Cario G; Escherich G; Panzer-Grümayer R; Astrahantseff K; Eggert A; Sramkova L; Attarbaschi A; Bourquin JP; Peters C; Henze G; von Stackelberg A;
    J Clin Oncol; 2019 Dec; 37(36):3493-3506. PubMed ID: 31644328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
    Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
    Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study.
    Ishida H; Yano M; Hasegawa D; Hori T; Hashii Y; Kato K; Deguchi T; Saito A; Sato A; Hori H; Horibe K; Imamura T
    Int J Hematol; 2021 Jun; 113(6):893-902. PubMed ID: 33641058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study.
    Pui CH; Rebora P; Schrappe M; Attarbaschi A; Baruchel A; Basso G; Cavé H; Elitzur S; Koh K; Liu HC; Paulsson K; Pieters R; Silverman LB; Stary J; Vora A; Yeoh A; Harrison CJ; Valsecchi MG;
    J Clin Oncol; 2019 Apr; 37(10):770-779. PubMed ID: 30657737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Outcomes of adults with Ph-negative B-cell acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of minimal residual disease].
    Ding Z; Han M; Chen S; Ma Q; Wei J; Pang A; Huang Y; Zhang X; Liang C; Liu X; Yao J; Li G; Cao Y; Feng S; Jiang E
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):587-92. PubMed ID: 26304084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission.
    Xue YJ; Suo P; Huang XJ; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Kong J; Zhang XH; Chen YH; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Cheng YF
    Br J Haematol; 2020 Mar; 188(5):757-767. PubMed ID: 31725190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults.
    Yu J; Luo Y; Wang L; Wang T; Ye M; Chen J; Ni X; Chen L; Gao L; Yang J
    Cancer Med; 2024 May; 13(10):e7310. PubMed ID: 38785213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
    den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
    Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study.
    Gidman W; Shah S; Zhang L; McKendrick J; Cong Z; Cohan D; Ottmann O
    Adv Ther; 2019 Nov; 36(11):3017-3029. PubMed ID: 31586302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retrospective Analysis of the Impact of Treatment on Prognosis in 44 Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia].
    Chen XP; Lv N; Li YH; Jing Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):14-8. PubMed ID: 26913386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients.
    Ribera J; Granada I; Morgades M; Vives S; Genescà E; González C; Nomdedeu J; Escoda L; Montesinos P; Mercadal S; Coll R; González-Campos J; Abella E; Barba P; Bermúdez A; Gil C; Tormo M; Pedreño M; Martínez-Carballeira D; Hernández-Rivas JM; Orfao A; Martínez-López J; Esteve J; Bravo P; Garcia-Guiñon A; Debén G; Moraleda JM; Queizán JA; Ortín X; Moreno MJ; Feliu E; Solé F; Ribera JM;
    Br J Haematol; 2019 Jul; 186(2):263-268. PubMed ID: 30916384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.
    Rau RE; Dai Y; Devidas M; Rabin KR; Zweidler-McKay P; Angiolillo A; Schore RJ; Burke MJ; Salzer WL; Heerema NA; Carroll AJ; Winick NJ; Hunger SP; Raetz EA; Loh ML; Wood BL; Borowitz MJ
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28929. PubMed ID: 33559396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland.
    Deeren D; Balabanov S; Nickel K; Giannopoulou C; Gonzalez-McQuire S; Kutikova L; Bouwmeester W; Spyridonidis A
    Leuk Res; 2020 Apr; 91():106334. PubMed ID: 32135394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.